GSK-3β polymorphism discriminates bipolar disorder and schizophrenia: a systematic meta-analysis

Mol Neurobiol. 2013 Dec;48(3):404-11. doi: 10.1007/s12035-013-8414-x. Epub 2013 Feb 27.

Abstract

Glycogen synthase kinase 3 (GSK-3) is a well-known conserved and ubiquitous protein kinase and playing a pivotal role in neurodevelopment, neurogenesis, learning/memory, and neuronal cell death. Dysfunction of GSK-3 had been seen in multiple neurodegenerative and psychiatric diseases. Bipolar disorder and schizophrenia are two common psychiatric diseases first occur in adolescence or young adulthood. They share similar risk genes as well as clinical symptoms, which make it is difficult to be discriminated from each other. Here, by using meta-analysis we reported that glycogen synthase kinase 3β promoter inactive mutant rs334558 may contribute to the development of schizophrenia not bipolar disorder. This might be used to distinguish these two diseases.

Publication types

  • Meta-Analysis
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bipolar Disorder / enzymology*
  • Bipolar Disorder / genetics*
  • Genetic Predisposition to Disease*
  • Glycogen Synthase Kinase 3 / genetics*
  • Glycogen Synthase Kinase 3 beta
  • Humans
  • Polymorphism, Single Nucleotide / genetics
  • Publication Bias
  • Risk Factors
  • Schizophrenia / enzymology*
  • Schizophrenia / genetics*

Substances

  • GSK3B protein, human
  • Glycogen Synthase Kinase 3 beta
  • Glycogen Synthase Kinase 3